QSAM is developing next generation nuclear medicines for the treatment of cancer and related diseases and conditions with high unmet need. The Company’s flagship product, Cyclosam®, is a clinical-stage bone seeking therapeutic radiopharmaceutical designed to safely and specifically deliver targeted radiation therapy to kill cancer cells in and near the bone. In animal studies and a recent single patient human trial, this approach appears to improve efficacy and safety. QSAM plans to commence additional trials during 2021.
QSAM Biosciences: Analyst See’s Massive Upside Potential As New Catalysts Lead 2021 Charge
